ccrcb cancer talk
TRANSCRIPT
From Local Research to Better Worldwide Cancer Treatment
Richard Kennedy McClay Professor in Medical Oncology
Queen’s UniversityVP Almac [email protected]
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
Spin-out companies
Staff• 40 Principle investigators• 39 Post-doctoral fellows• 10 Clinical research fellows• 58 PhD students (5 Del students/year)• 8 MRes students• 39 BSc students• 25 Summer Students
Over 200 researchers Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
5- 10 years
The Translational Research Pipeline at QUB
Clinician scientistsAcademic pathologistsAcademic surgeonsClinical StatisticiansAcademic geneticistsAcademic public healthAcademic RadiologistsMedicinal chemistryBasic scientistsBioinformatitions
Clinician scientistsClinical TrialistsMedicinal chemistsIndustrial cliniciansLocal industryPharmaceutical industry
Clinical TrialistsAcademic pathologistsAcademic surgeonsClinical statisticiansAcademic RadiologistsNHS PhysiciansTrial coordinatorsPatient Advocates
The Translational Research Pipeline at QUB
Highlights
• ColDx
• DDRD Breast cancer assay
• MERCURIC study
• ALM201 study
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
ColDx• Almac and QUB Analysed 500 colon cancers • Developed a gene based assay to predict recurrence of
stage II colon cancer• Validated in an international trial cohort of 120 patients
from 12 centres 2011- published in JCO
Survival yrs
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
ColDx
• Also validated by CALGB collaborative group 2013• Will enter clinic in 2014
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
Application of Colon Cancer ColDx Assay in Clinic
Almac Diagnostics 2014
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
Breast Cancer Test
• Although chemotherapy can help cure breast cancer not all patients benefit.
• Almac collaborated with CCRCB to analyze over 300 breast cancer samples to better understand the disease.
• Have developed a test that can personalize chemotherapy on an individual basis.
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
DDRD Assay Predicts Benefit from Chemotherapy
• Health Economic analysis has shown the test to be cost saving
• Entering clinical practice 2015 in collaboration with Genomic Health (USA)
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
Clinical Use of The DDRD Assay
Almac Diagnostics 2014
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
• CCRCB have identified a novel way to treat colorectal cancer that is mutant for the KRAS gene (Van Schaeybroeck and Johnston)
• A 6 million Euro FP7 grant has been awarded for an international clinical study (Schaeybroeck, Johnston and Wilson).
• 8 centres involved.
• QUB/NICTU is the coordinating centre.
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
ALM201• QUB scientists have discovered a new way to inhibit the
development of blood vessels in cancer (Robson).• In collaboration with Almac have developed a new drug
(ALM201).• Pre-clinical work suggests very low toxicity.• Clinical trial in ovarian cancer throughout UK begins April
2014, led from Belfast (Wilson).
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
ALM201 study Phase I
First relapse ovarian cancer
Angiogenesis test
Positive Negative
ALM201 Standard therapy
Radiological ResponseProgression free survival
Richard Wilson: ECMC Belfast
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy
SUMMARY
Comprehensive Cancer Centre; focused on discovery and application to improve patient outcomes
Integrated and collaborative scientific and clinical research programmes focused on clinically-relevant issues
Creation of partnerships with existing biotech/pharma to deliver clinical application of research
Innovative discovery is underpinning our international and clinical and scientific programmes in Personalized Medicine
Cen
tre
for
Can
cer
Res
earc
h &
Cel
l Bio
logy